# Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

> **NCT00424840** · PHASE1 · TERMINATED · sponsor: **University of Massachusetts, Worcester** · enrollment: 12 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Bortezomib 1.3 mg/m2
- **DRUG:** Bortezomib 1.6 mg/m2
- **DRUG:** Bortezomib 1.8 mg/m2
- **DRUG:** Carboplatin AUC 6
- **DRUG:** Bevacizumab
- **DRUG:** Taxotere

## Key facts

- **NCT ID:** NCT00424840
- **Lead sponsor:** University of Massachusetts, Worcester
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2019-02-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424840, "Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00424840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*